Mark A. Velleca

Mark Velleca, M.D., Ph.D. was most recently Chief Executive Officer of G1 Therapeutics, where he grew the company from Series A through IPO and led the development of its first therapy (COSELA™) from preclinical to FDA approval. Previously, he served as Executive Vice President at the Leukemia & Lymphoma Society (LLS). Prior to LLS, Mark was co-founder and Senior Vice President of CGI Pharmaceuticals, where he managed the company from its inception through clinical trials of multiple drug candidates. After Gilead Sciences acquired CGI, he served as a Senior Advisor to Gilead in R&D Strategy and Corporate Development. Earlier in his career, Mark was an attending physician at Yale New Haven Hospital and on the faculty of the Yale University School of Medicine.

Currently, Mark is a Senior Advisor and board member at G1 Therapeutics, board member at IMMvention Therapeutix, board chair at Turbine AI, and a Venture Partner at Hatteras Venture Partners.

Mark earned an M.D. and Ph.D. from Washington University in St. Louis and a B.S. from Yale University.